Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $24.65 | Total: $123.25 |
| 1 | 10 | $20.88 | Total: $208.80 |
| 1 | 25 | $17.69 | Total: $442.25 |
| 1 | 50 | $15.08 | Total: $754.00 |
| 1 | 100 | $13.05 | Total: $1,305.00 |
Overview
Gilteritinib hemifumarate (ASP2215 hemifumarate) is a potent ATP-competitive dual FLT3 (IC50: 0.29 nM) and AXL (IC50: 0.73 nM) inhibitor for the treatment of relapsed or refractory FLT3 mutant AML.
Chemical Properties
| Molecular Formula | C29H44N8O3.12C4H4O4 |
| Molecular Weight | 610.75 |
| CAS Numbers | 1254053-84-3 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | C(=CC(O)=O)C(O)=O.N(C=1C(C(N)=O)=NC(CC)=C(NC2CCOCC2)N1)C3=CC(OC)=C(C=C3)N4CCC(CC4)N5CCN(C)CC5 |
Storage and Handling
0C Short Term, -20C Long Term
References
Yoko Ueno,et al. ASP2215, a novel FLT3AXL inhibitor Preclinical evaluation in combination with cytarabine and anthracycline in acute myeloid leukemia [AML].Journal of Clinical Oncology 2014 32 15_suppl, 7071